August 12, 2022 05:55 AM EDTUpdated 06:45 AM

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Copy Chief

Editor

Senior Reporter

Sign up to read this article for free.

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board